Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation

Circulation

Volumn 115, Issue 4, 2007, Pages 493-500

  Pires, Nuno M M ^a,b   Pols, Thijs W H ^c   De Vries, Margreet R ^a   Van Tiel, Claudia M ^c   Bonta, Peter I ^c   Vos, Mariska ^c   Arkenbout, E Karin ^c   Pannekoek, Hans ^c   Jukema, J Wouter ^b   Quax, Paul H A ^a,b   De Vries, Carlie J M ^c  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Muscle, smooth; Receptors, cytoplasmic and nuclear; Restenosis; Stents; Transcription factors

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; MERCAPTOPURINE; MESSENGER RNA; NUCLEAR RECEPTOR NUR77; POLYCAPROLACTONE; SMALL INTERFERING RNA; STAUROSPORINE; THYMIDINE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFECT; ELUTION; EXPERIMENTAL MODEL; FEMORAL ARTERY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOTHESIS; IN-STENT RESTENOSIS; INFLAMMATION; INTIMA; LOCAL THERAPY; MALE; MOUSE; NONHUMAN; OBSERVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SMOOTH MUSCLE FIBER; SUSTAINED DRUG RELEASE; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE; WILD TYPE;

6-MERCAPTOPURINE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL DIVISION; CELLS, CULTURED; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG IMPLANTS; FEMORAL ARTERY; HUMANS; MALE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUNICA INTIMA; UMBILICAL ARTERIES;

EID: 33846620640     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.626838     Document Type: Article

References (31)

1. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 1998;98:224-233.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo A, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
4. van der Hoeven BL, Pires NM, Warda HM, Oemrawsingh PV, van Vlijmen BJ, Quax PH, Schalij MJ, van der Wall EE, Jukema JW. Drug-eluting stents: results, promises and problems. Int J Cardiol. 2005;99:9-17.
5. de Vries CJ, van Achterberg TA, Horrevoets AJ, ten Cate JW, Pannekoek H. Differential display identification of 40 genes with altered expression in activated human smooth muscle cells: local expression in atherosclerotic lesions of smags, smooth muscle activation-specific genes. J Biol Chem. 2000;275:23939-23947.
6. Arkenbout EK, de Waard V, van Bragt M, van Achterberg TA, Grimbergen JM, Pichon B, Pannekoek H, de Vries CJ. Protective function of transcription factor TR3 orphan receptor in atherogenesis: decreased lesion formation in carotid artery ligation model in TR3 transgenic mice. Circulation. 2002;106:1530-1535.
7. Maruyama K, Tsukada T, Ohkura N, Bandoh S, Hosono T, Yamaguchi K. The NGFI-B subfamily of the nuclear receptor superfamily. Int J Oncol. 1998;12:1237-1243.
8. Hsu HC, Zhou T, Mountz JD. Nur77 family of nuclear hormone receptors. Curr Drug Targets Inflamm Allergy. 2004;3:413-423.
9. Winoto A, Littman DR. Nuclear hormone receptors in T lymphocytes. Cell. 2002;109:S57-S66.
10. Giguere V. Orphan nuclear receptors: from gene to function. Endocr Rev. 1999;20:689-725.
11. Wansa KD, Harris JM, Yan G, Ordentlich P, Muscat GE. The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine. J Biol Chem. 2003;278:24776-24790.
12. Estlin EJ. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine. Cancer Treat Rev. 2001;27:351-363.
13. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20:1149-1157.
14. McGeown MG, Douglas JF, Donaldson RA, Hill CM, Kennedy JA, Loughridge WG, Middleton D. Ten-year results of renal transplantation with azathioprine and prednisolone as only immunosuppression. Lancet. 1988;1:983-985.
15. Quax PH, Lamfers ML, Lardenoye JH, Grimbergen JM, de Vries MR, Slomp J, de Ruiter MC, Kockx MM, Verheijen JH, van Hinsbergh VW. Adenoviral expression of a urokinase receptor targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation. 2001;103:562-569.
16. Pires NM, van der Hoeven BL, de Vries MR, Havekes LM, van Vlijmen BJ, Hennink WE, Quax PH, Jukema JW. Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff. Biomaterials. 2005;26:5386-5394.
17. Philips A, Maira M, Mullick A, Chamberland M, Lesage S, Hugo P, Drouin J. Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Mol Cell Biol. 1997;17:5952-5959.
18. Kolluri SK, Bruey-Sedano N, Cao X, Lin B, Lin F, Han YH, Dawson MI, Zhang XK. Mitogenic effect of orphan receptor TR3 and its regulation by MEKK1 in lung cancer cells. Mol Cell Biol. 2003;23:8651-8667.
19. Ordentlich P, Yan Y, Zhou S, Heyman RA. Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1. J Biol Chem. 2003;278:24791-24799.
20. Simon DI, Dhen Z, Seifert P, Edelman ER, Ballantyne CM, Rogers C. Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. J Clin Invest. 2000;105:293-300.
21. de Waard V, Arkenbout EK, Vos M, Mocking AI, Niessen HW, Stooker W, de Mol BA, Quax PH, Bakker EN, VanBavel E, Pannekoek H, de Vries CJ. TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. Am J Pathol. 2006;168:2027-2035.
22. Wansa KD, Muscat GE. TRAP220 is modulated by the antineoplastic agent 6-mercaptopurine, and mediates the activation of the NR4A subgroup of nuclear receptors. J Mol Endocrinol. 2005;34:835-848.
23. Martinez-Gonzalez J, Rius J, Castello A, Cases-Langhoff C, Badimon L. Neuron-derived orphan receptor-1 (NOR-1) modulates vascular smooth muscle cell proliferation. Circ Res. 2003;92:96-103.
24. Martinez-Gonzalez J, Badimon L. The NR4A subfamily of nuclear receptors: new early genes regulated by growth factors in vascular cells. Cardiovasc Res. 2005;65:609-618.
25. Tidd DM, Paterson ARP. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 1974;34:738-746.
26. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65:240-261.
27. Hollander AAMJ, van Saasse JLCM, Kootte AMM, van Dorp Wt, van Bockel HJ, van Es LA, van der Woude FJ. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet. 1995;345:610-614.
28. Sutherland F, Burgess E, Klassen J, Buckle S, Paul LC. Post-transplant conversion from cyclosporin to azathioprine: effect on cardiovascular risk profile. Transplant Int. 1993;6:129-132.
29. van den Dorpel MA, Ghanem H, Rischen-Vos J, Man in't Veld AJ, Jansen H, Weimar W. Conversion from CsA to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int. 1997;51:1608-1612.
30. van den Dorpel MA, Levi M, Ijzermans JN, ten Cate JW, Weimar W. Beneficial effects of conversion from CsA to AZA on fibrinolysis in renal transplant recipients. Arterioscler Thromb Vasc Biol. 1999;19:1555-1558.
31. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2:807-818.